Loading…
Major Korean R&D-focused pharmaceutical company known for global licensing deals in diabetes/obesity and oncology drugs.
Major Korean R&D-focused pharmaceutical company known for global licensing deals in diabetes/obesity and oncology drugs.
Sells prescription drugs in Korea, often combination pills built from existing molecules, through hospitals and wholesalers; that steady business funds research. Licensing deals with larger drugmakers add lumpy milestone payments tied to partners' trial progress. Hanmi Science is the holding company above it.
Moat: narrow (IP / patents, brand). One of few Asian pharma companies with a globally licensed novel-drug pipeline.
Headquarters: Seoul, South Korea · Founded: 1973 · Employees: 2,382
Size HanmiPharm (128940.KS) is a South Korea Health Care company (Pharmaceuticals: Major) with a market value of $4.36B, the 86th largest of 495 South Korea companies the cockpit tracks. Shares closed at ₩467,000 on 6 Nov 2026.
Performance Over six months the shares gained 1.5%, against +5.0% for the median peer and -24.5% for the South Korea market (cap-weighted) — 7th lowest of 20 in its peer set.
Growth Revenue grew 13.9% over the last twelve months (peer median +6.0%); the operating margin is 15.7% (peer median 15.7%).
Valuation It trades at 16.8× forward earnings against a peer median of 31.4× (5th cheapest of 18).
Price implies For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is -3 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 7.6 points above its cost of capital (5.9% WACC).
Next results Next results expected around 10 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩1.67T | ₩1.55T | ₩1.50T | ₩1.49T | ₩1.33T |
| Revenue growth | — | +3% | 0% | +12% | — |
| Gross profit | n/a | ₩880B | ₩827B | ₩836B | ₩730B |
| EBITDA | n/a | ₩323B | ₩310B | ₩323B | ₩250B |
| Net income | ₩191B | ₩170B | ₩121B | ₩146B | ₩82.8B |
| Free cash flow | n/a | ₩130B | ₩154B | ₩189B | ₩133B |
| Capital expenditure | n/a | ₩80.7B | ₩67.0B | ₩47.7B | ₩69.4B |
| Total debt | n/a | ₩434B | ₩497B | ₩573B | ₩678B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| HanmiPharm 128940.KS | $4.36B | +2% | +14% | 16% | 16.8× | 5.0% |
| Yuhan 000100.KS | $4.05B | -12% | +5% | 5% | 38.6× | 20.2% |
| SKBP 326030.KS | $5.12B | -11% | +39% | 35% | 21.6× | 0.5% |
| Novo Nordisk A/S NOVO-B.CO | $190B | -7% | +6% | 48% | 11.9× | 0.1% |
| Lilly (Eli) LLY | $1.27T | +43% | +46% | 51% | 28.9× | 5.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 128940.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -12.6% | +6.5% | lowest of 20 |
| 6-month return | +1.5% | +5.0% | 7th lowest of 20 |
| Distance from 52-week high | -27.6% | -24.4% | 11th highest of 21 |
| Revenue growth (TTM) | +13.9% | +6.0% | 8th highest of 20 |
| Operating margin | 15.7% | 15.7% | 10th lowest of 20 |
| Forward P/E | 16.8× | 31.4× | 5th cheapest of 18 |
| Growth the price implies (Req g, 7 yrs) | 5.0% | 8.8% | 8th least demanding of 17 |
| Growth delivered (Del g) | +7.5% | +6.0% | 8th highest of 17 |
| Hurdle (Req g minus delivered) | -2.5 pp | -3.2 pp | 8th most demanding of 17 |
| ROIC minus cost of capital | +7.6 pp | +7.3 pp | 9th highest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| HanmiPharm 128940.KS | South Korea | $4.36B | +2% | +14% | 16% | 16.8× | 5.0% | +7.5% |
| Ajanta Pharma AJANTPHARM.NS | India | $4.37B | +7% | +25% | 25% | 32.2× | 23.8% | +13.8% |
| Definium Therapeutics DFTX | United States | $4.47B | +51% | n/a | n/a | n/a | n/a | n/a |
| Sunshine Guojian Pharmaceutical (Shanghai) 688336.SS | China | $4.47B | -34% | +227% | 74% | 46.9× | 3.3% | +45.1% |
| Emcure Pharmaceuticals EMCURE.NS | India | $4.47B | +33% | +21% | 16% | 33.9× | 14.9% | +12.7% |
| Camurus CAMX.ST | Sweden | $4.52B | +47% | 0% | 37% | 48.5× | 10.4% | +46.5% |
| GlaxoSmithKline Pharmaceuticals GLAXO.NS | India | $4.53B | +2% | +12% | 33% | 35.9× | 25.2% | +5.5% |
| Legend Biotech Corp. Sponsored ADR LEGN | United States | $4.53B | -17% | +60% | -4% | 64.5× | n/a | n/a |
| Guangzhou Baiyunshan Pharmaceutical 0874.HK | Hong Kong | $4.56B | -23% | +6% | 3% | 7.3× | 0.7% | +4.0% |
| Tianjin Pharmaceutical Da Ren Tang 600329.SS | China | $4.11B | +4% | -13% | 20% | 31.4× | 17.8% | -5.8% |
| Shanghai Junshi Biosciences 1877.HK | Hong Kong | $4.08B | -39% | +36% | -14% | n/a | n/a | n/a |
| HUBEI JUMPCAN PHARMACEUTICAL 600566.SS | China | $4.05B | +6% | -4% | 32% | 14.9× | -11.5% | +0.3% |
| Yuhan 000100.KS | South Korea | $4.05B | -12% | +5% | 5% | 38.6× | 20.2% | +6.2% |
| Humanwell Healthcare (Group) 600079.SS | China | $4.71B | +3% | -3% | 16% | 13.4× | -6.8% | +3.0% |
| Travere Therapeutics TVTX | United States | $4.76B | +16% | +49% | -3% | 16.9× | 16.7% | +19.9% |
| Siegfried SFZN.SW | Switzerland | $3.98B | -10% | +4% | 16% | 17.8× | n/a | n/a |
| Liquidia LQDA | United States | $3.97B | +5% | +2,234% | 37% | 32.9× | 0.7% | +192.5% |
| Novast Laboratories 301569.SZ | China | $4.82B | n/a | +3% | 27% | n/a | 42.6% | +3.1% |
| Laboratorios Farmaceuticos Rovi ROVI.MC | Spain | $3.89B | +15% | +3% | 20% | 22.3× | 1.5% | +12.1% |
| Zhejiang Huahai Pharmaceutical 600521.SS | China | $3.86B | +8% | +10% | 12% | 22.1× | 7.3% | +5.9% |
| Santen Pharmaceutical 4536.T | Japan | $3.86B | +17% | -1% | 16% | 15.6× | -5.2% | +3.2% |